Results 61 to 70 of about 118,558 (284)

Relationship of Work Productivity and Social Activities with Disease Activity in Ankylosing Spondylitis Patients

open access: yesCam & Sakura Medical Journal
Objective: Ankylosing spondylitis (AS) is a chronic, inflammatory disease that starts in the most productive years of life and causes severe disability in at least 1/3 of patients.
Ömer Faruk Bucak   +3 more
doaj   +1 more source

Clinical study of patient with Ankylosing Spondylitis

open access: yesJournal of Pharmacopuncture, 2006
Object : This study is designed in order to evaluate oriental medical treatment of ankylosing spondylitis. Methods : The authors observed patient by ROM & VAS for operated acupuncture treatment, herbal medicine treatment and physiotherapy Conclusion :
Lee Jae-Min, Hong Kwon-eui
doaj   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

open access: yes, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro   +5 more
core   +3 more sources

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort

open access: yesAnnals of the Rheumatic Diseases, 2017
Objectives To analyse the impact of tumour necrosis factor inhibitors (TNFis) on spinal radiographic progression in ankylosing spondylitis (AS). Methods Patients with AS in the Swiss Clinical Quality Management cohort with up to 10 years of follow-up and
Christoph Molnar   +15 more
semanticscholar   +1 more source

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

open access: yesAdvanced Science, EarlyView.
This review provides a systematic comparison of extracellular vesicles (EVs) from both mammalian and plant sources in the context of autoimmune diseases. It highlights their emerging roles as precision biomarkers and engineered therapeutic platforms.
Yufei Wu   +6 more
wiley   +1 more source

Ankylosing Spondylitis: A summary and review [PDF]

open access: yes, 1993
A review of the etiology, clinical, radiological and laboratory presentation, differential diagnosis and management.
Walker, B.F.
core   +1 more source

Artificial Intelligence for Bone: Theory, Methods, and Applications

open access: yesAdvanced Intelligent Discovery, EarlyView.
Advances in artificial intelligence (AI) offer the potential to improve bone research. The current review explores the contributions of AI to pathological study, biomarker discovery, drug design, and clinical diagnosis and prognosis of bone diseases. We envision that AI‐driven methodologies will enable identifying novel targets for drugs discovery. The
Dongfeng Yuan   +3 more
wiley   +1 more source

Brazilian-portuguese version and applicability questionnaire of the mobility index for ankylosing spondyliti Versão em língua portuguesa do Brasil e a reprodutibilidade do questionário de índice de mobilidade para espondilite anquilosante

open access: yesClinics, 2007
PURPOSE: To translate and adapt the Bath Ankylosing Spondylitis Methodology Index (BASMI) - a metrological measurement for the assessment of patients with ankylosing spondylitis to Brazilian-Portuguese and to analyze the applicability of the ...
Samuel Katsuyuki Shinjo   +3 more
doaj   +1 more source

Histopathology of the gut in rheumatic diseases [PDF]

open access: yes, 2018
The gastrointestinal tract regulates the trafficking of macromolecules between the environment and the host through an epithelial barrier mechanism and is an important part of the immune system controlling the equilibrium between tolerance and immunity ...
Ciccia F.   +4 more
core   +1 more source

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

open access: yesThe Lancet, 2018
BACKGROUND At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs ...
D. Heijde   +15 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy